New medications for lowering a1c
Pro Research Analysisby 
Searched over 200M research papers
New Medications for Lowering A1C: Drug Classes and Effectiveness
Several new classes of medications have emerged for lowering hemoglobin A1C (HbA1c) in people with type 2 diabetes. These include sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors, in addition to traditional agents like metformin, sulfonylureas, and thiazolidinediones 1378+1 MORE.
SGLT2 Inhibitors and GLP-1 Receptor Agonists
SGLT2 inhibitors and GLP-1 receptor agonists are among the most notable new drug classes. SGLT2 inhibitors, such as canagliflozin, and GLP-1 receptor agonists, such as liraglutide, are increasingly used as second-line therapies after metformin 2310. Studies show that liraglutide is particularly effective, with the lowest 1-year cumulative incidence of failing to achieve HbA1c below 7.0% compared to other second-line agents like sitagliptin, canagliflozin, and glimepiride . GLP-1 agonists also show a clear association between greater HbA1c reduction and lower risk of cardiovascular events, a benefit not seen as strongly with SGLT2 or DPP-4 inhibitors .
DPP-4 Inhibitors
DPP-4 inhibitors, such as sitagliptin, are another newer class. While they are less effective than metformin for lowering A1C, they are often used in combination with other agents. Adding sitagliptin to pioglitazone, for example, can further decrease HbA1c synthesis rates, showing the benefit of combination therapy 14. However, DPP-4 inhibitors generally provide a more modest reduction in A1C compared to GLP-1 agonists and SGLT2 inhibitors 137.
Other Newer Agents and Combinations
Ranolazine, a drug originally approved for angina, has also been shown to lower A1C and fasting plasma glucose when added to standard diabetes treatments, especially in patients with poorly controlled diabetes and cardiovascular disease . Fixed combination products and regimens that include GLP-1 receptor agonists with insulin or other oral agents can improve glycemic control and reduce the risk of hypoglycemia compared to insulin alone 159.
Comparative Effectiveness and Safety
Most oral antidiabetic agents lower A1C by 0.5–1.25%, with thiazolidinediones and sulfonylureas at the higher end of this range . The benefit of these medications is most apparent within the first 4–6 months of therapy . GLP-1 receptor agonists, especially liraglutide, are effective at achieving A1C targets with a lower risk of hypoglycemia compared to insulin-based regimens 259. Combination therapies, such as glinide plus thiazolidinedione or premixed insulin plus GLP-1 agonist, can offer high efficacy for glycemic control while minimizing severe hypoglycemia .
Trends in Clinical Practice
Recent years have seen a shift in prescribing patterns, with SGLT2 inhibitors and GLP-1 receptor agonists now accounting for a significant portion of second-line therapy after metformin . Sulfonylureas remain common, but the use of newer agents is increasing, reflecting updated clinical guidelines and growing evidence of their benefits .
Conclusion
New medications for lowering A1C in type 2 diabetes include SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors. Among these, GLP-1 receptor agonists like liraglutide are particularly effective for A1C reduction and cardiovascular risk reduction. SGLT2 inhibitors and DPP-4 inhibitors also play important roles, especially in combination therapies. The choice of medication should consider efficacy, risk of hypoglycemia, patient characteristics, and cost. Recent trends show increasing use of these newer agents as part of individualized diabetes management strategies 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Diabetes update: new drugs to manage type 2 diabetes.
Newer diabetes drugs like exenatide and gliptins show promise for lowering A1c and BMI, but their impact on mortality and morbidity remains unclear.
785-P: Comparative Effectiveness of Second-Line Glucose-Lowering Medications—Emulation of a Target Trial Using Real-World Data
Liraglutide is the most effective second-line type 2 diabetes medication for achieving HbA1c 7.0%, followed by sitagliptin, canagliflozin, and glimepiride.
The Effect of Oral Antidiabetic Agents on A1C Levels
Oral antidiabetic agents show the most benefit in the first 4 to 6 months, with A1C levels unlikely to fall more than 1.5% on average, and pretreated A1C levels have a modest effect on the fall of A1C levels in response to treatment.
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
This algorithm helps physicians manage type 2 diabetes by aiming for a hemoglobin A1c of 6.5% or less, prioritizing safety, efficacy, simplicity, patient adherence, and cost, and monitoring therapy frequently.
DOI